Resources from the same session
729MO - Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatment
Presenter: Ignacio Melero
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
730MO - First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies
Presenter: Martin Gutierrez
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
731MO - A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Glenn Hanna
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 729MO, 730MO and 731MO
Presenter: Inge-Marie Svane
Session: Mini Oral session: Investigational immunotherapy
Resources:
Slides
Webcast
732MO - The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial
Presenter: Stephane Champiat
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
733MO - γδT cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects
Presenter: Joris Van De Haar
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
734MO - Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy
Presenter: Benjamin Fairfax
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
735MO - Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors
Presenter: David S Hong
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
736MO - Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
Presenter: Chrisann Kyi
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
737MO - EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers
Presenter: Weijia Fang
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast